CONCLUSIONS CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was reported
it also contains a compound that mimics a second gut hormone, GIP (glucose-dependent insulinotropic polypeptide)
Patient-facing guidance from MedlinePlus emphasizes coordinating dose changes with your clinician to avoid uncontrolled glucose and adverse effects, not self-adjusting on your own
Research status Reta is Phase 3 investigational
Reviewed by Bambi Plumlee, MSN, RN, founder and nurse injector, with medical oversight from Medical Director Dr
Patients should be advised to stop Saxenda and seek urgent medical attention if they experience severe or persistent abdominal pain (which may indicate pancreatitis), symptoms of gallbladder disease, or signs of dehydration